DXR - Daxor Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
9.61
0.00 (0.00%)
At close: 3:09PM EST
Stock chart is not supported by your current browser
Previous Close9.61
Open0.00
Bid0.00 x 1000
Ask0.00 x 800
Day's Range9.35 - 9.72
52 Week Range5.76 - 19.95
Volume8
Avg. Volume2,648
Market Cap36.02M
Beta (3Y Monthly)-0.51
PE Ratio (TTM)181.39
EPS (TTM)0.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-01-05
1y Target Est20.00
  • GlobeNewswire

    Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA. Researchers at Yale utilized Daxor’s unique technology to analyze the volume shifts associated with the drug and were able to determine that there is a significant and sustained blood volume shift that is unique to this diuretic that may explain why diabetic HF patients have been shown in recent trials to benefit from its use.

  • GlobeNewswire

    Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019

    NEW YORK, Nov. 12, 2019 -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume.

  • Read This Before Judging Daxor Corporation's (NYSEMKT:DXR) ROE
    Simply Wall St.

    Read This Before Judging Daxor Corporation's (NYSEMKT:DXR) ROE

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • GlobeNewswire

    Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas at the Hilton Austin on Tuesday, October 15th at 1:30 PM (CT). Mr. Feldschuh will provide an overview of the Company’s business model and growth strategy and will be available for one-on-one meetings.

  • GlobeNewswire

    Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of Hypertension

    NEW YORK, Sept. 24, 2019 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • GlobeNewswire

    New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from the Mayo Clinic showing the benefits of the BVA technology in chronic heart failure patients. The study was presented on September 12th during the 23rd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Pennsylvania Convention Center in Philadelphia, PA. Dr. Wayne Miller of the Mayo Clinic in Rochester MN took part in an expert panel session focused on diagnostic measures to assess heart failure patients to determine optimal treatment strategies.

  • GlobeNewswire

    Daxor Corporation to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the 23rd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Philadelphia Convention Center in Philadelphia, PA from September 13-16th, 2019. “The HFSA’s Annual Scientific Meeting is a premier venue to increase awareness and utilization of Daxor’s blood volume diagnostic test with key thought leaders and decision makers focused on heart failure research and patient care,” said Michael Feldschuh, CEO of Daxor Corporation.

  • GlobeNewswire

    Daxor Corporation Announces a 38 Percent Rise in BVA-100 Cardiology Kit Sales and Net Gain of $498,111 for Six Months in Filing of Form N-CSR for June 30, 2019

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2019. Form N-CSR for the period ended June 30, 2019 is available on the Securities and Exchange Commission (“SEC”) website at www.sec.gov  as well as on the Company’s website at www.daxor.com.

  • How Do Daxor Corporation’s (NYSEMKT:DXR) Returns Compare To Its Industry?
    Simply Wall St.

    How Do Daxor Corporation’s (NYSEMKT:DXR) Returns Compare To Its Industry?

    Today we'll evaluate Daxor Corporation (NYSEMKT:DXR) to determine whether it could have potential as an investment...

  • GlobeNewswire

    Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the acquisition of Daxor's BVA-100 blood volume analyzer as part of standard clinical practice in a leading academic health center in the Pacific Northwest following a successful evaluation trial. “The BVA-100 provides a simple, inexpensive, objective measurement of volume status and composition,” said Michael Feldschuh, CEO of Daxor Corporation. "We are pleased to provide physicians at this leading hospital with accurate, actionable volume information to better inform treatment strategies leading to optimal patient outcomes and improved quality of life.

  • GlobeNewswire

    Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the BVA-100® Blood Volume Diagnostic Test

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces a new research initiative with a leading hospital in the Southeast using Daxor's BVA-100 blood volume measurement test to help guide the management of surgical blood loss during orthopedic surgery. "Hemodynamic instability and anemia can often be associated with significant adverse outcomes, especially in orthopedic surgical patients,” said Michael Feldschuh, CEO of Daxor Corporation.

  • GlobeNewswire

    Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, chief executive officer of Daxor Corporation, will be a featured presenter at the LD Micro Invitational Conference on Tuesday, June 4th at 9:40 AM Pacific Time. Interested investors may request a meeting time by contacting Bret Shapiro at COREIR either by calling 1-561-479-8566 or emailing brets@coreir.com. Daxor Corporation is an innovative medical instrumentation and biotechnology company.

  • GlobeNewswire

    Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces a new partnership with a leading hospital in North Carolina to integrate Daxor's BVA-100 blood volume measurement test as part of standard clinical practice. “Blood volume analysis allows us to provide a strategic and tactical approach to fluids, diuretics and transfusion in patients with complex illnesses that allows for improved mortality and morbidity as well as economic savings,” said Henry D. Cremisi, M.D., a specialist in nephrology & clinical research.

  • Our Take On Daxor Corporation's (NYSEMKT:DXR) CEO Salary
    Simply Wall St.

    Our Take On Daxor Corporation's (NYSEMKT:DXR) CEO Salary

    Michael Feldschuh has been the CEO of Daxor Corporation (NYSEMKT:DXR) since 2016. This analysis aims first to contrast...

  • GlobeNewswire

    Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today addressed and corrected an erroneous and misleading article published March 20, 2019, at 12:09pm eastern time on Seeking Alpha.com by Douglas W. House, Seeking Alpha News Editor, in which Mr. House erroneously stated, “Thinly traded nano cap Daxor (DXR -11.3%) is down on 50% higher volume, albeit on turnover of only 88K shares, following yesterday's corporate overview at the ROTH Conference in Southern California. Upon learning of Mr. House’s and Seeking Alpha’s publishing of this erroneous article and misstatements, Daxor contacted the editor to demand a retraction and correction that Daxor has one product, and moreover that it has generated no sales to date.

  • GlobeNewswire

    Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

    NEW YORK, March 15, 2019 -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood.

  • GlobeNewswire

    Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2018. For the second straight year, Daxor reported that kit sales rose over 18% year-on-year in the cardiology segment, driven by increasing awareness of the value of blood volume analysis to improve heart failure outcomes through reduced mortality and readmissions. A landmark study on the use of the BVA-100 to guide heart failure treatment was published in the Journal of the American College of Cardiology – Heart Failure (“JACC-HF”) in November of 2018.

  • GlobeNewswire

    New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the University of Hawaii John A. Burns School of Medicine showing improved ease of use with the BVA-100 test by reducing the number of blood samples and that direct blood volume analysis provides clinicians with important information to inform better treatment decisions in the critically-ill. Three new studies were presented during the 48th Annual Society of Critical Care Medicine Congress in San Diego, CA. One study, “Reducing Blood Sampling for Circulating Blood Volume Determination: A Pilot Feasibility,” showed a 97% agreement in critically-ill cohorts whose blood volumes were compared using one blood draw versus five blood draws.

  • GlobeNewswire

    Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

    Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 48th Congress at the San Diego Convention Center in San Diego, CA from February 17-19th, 2019. Research from the University of Hawaii John A. Burns School of Medicine relating to the use of Daxor’s BVA-100 blood volume analyzer in Critical Care use is scheduled to be presented.

  • GlobeNewswire

    Daxor Corporation Appoints Guido Manzo, Vice President of Sales

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of Sales. "Guido joins Daxor with 35 years of experience in medical sales and marketing focused on central lab and point-of-care testing.

  • GlobeNewswire

    Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

    Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital in Wausau Wisconsin has acquired a BVA-100 Blood Volume Analyzer. Best known for its world-class cardiovascular program, Aspirus Wausau Hospital also provides leading edge cancer, trauma, women’s health, and spine and neurological care. Aspirus Wausau Hospital is the flagship of the Aspirus system that serves patients in 14 counties across northern and central Wisconsin, as well as the Upper Peninsula of Michigan.